EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification

Jiajia Yuan, Lin Shen, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Hongming Pan, Yusheng Wang, Xiaotian Zhang, Zhi Peng und 8 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.70091 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Jiajia Yuan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital and Institute, Beijing, China. Hauptthemen laut MEDLINE: Gene Amplification, Receptor, Fibroblast Growth Factor, Type 2, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infigratinib, an FGFR1‐3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients. In this phase II, open‐label, single‐arm study in China, patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) harboring FGFR2 gene amplification received 125 mg infigratinib orally once daily in a “3 weeks on, 1 week off” schedule for 28‐day cycles. Plasma PK parameters were calculated with a non‐compartmental model. Data were available from 21 patients (19 GC and two GEJ). After a single dose, peak infigratinib plasma concentration was reached at a median time of 3.1 h, with geometric mean C max of 85.9 ng/mL and AUC 0‐ t of 637 h*ng/mL. After 21‐day dosing, geometric mean infigratinib C max,ss of 204 ng/mL was reached at a median of 4.0 h; geometric mean AUC 0‐24,ss was 3060 h*ng/mL. The geometric mean R ac , Cmax (%CV) and R ac , AUC0‐24 (%CV) of infigratinib was 2.5 (113.8) and 5.1 (138.2), respectively. A steady state of infigratinib was reached after continuous dosing for 15 days. The metabolites accounting for >10% of infigratinib were BHS697 and CQM157. The PK profiles of infigratinib and its metabolites in Chinese patients with GC or GEJ were largely consistent with known PK profiles of infigratinib from global populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene AmplificationReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralAntineoplastic AgentsChinaEast Asian PeopleProtein Kinase InhibitorsPyrimidinesPhenylurea Compounds

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsPyrimidinesReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humaninfigratinibPhenylurea Compounds

Autor:innen und Institutionen

  • Peking University Cancer Hospital and Institute, Beijing, China.
  • Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
  • Hubei Cancer Hospital, Wuhan, China.
  • Fujian Provincial Cancer Hospital, Fuzhou, China.
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
  • The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Lingli Zhang, Lin Song, Qiao Sun

Zitieren

APA

Yuan, J., Shen, L., Liu, T. S., Xu, H., Yang, J., Wei, J., Jiang, H., Deng, Y., Pan, H., Wang, Y., Zhang, X., Peng, Z., Qi, C., Zhang, L., Hsu, P., Song, L., Mu, L., Sun, Q., Gong, J., & Lyu, C. (2024). Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification. Clinical and Translational Science. https://doi.org/10.1111/cts.70091

Vancouver

Yuan J, Shen L, Liu TS, Xu H, Yang J, Wei J, et al. Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification. Clinical and Translational Science. 2024. doi:10.1111/cts.70091

BibTeX
@article{Yuan2024,
  author = {Yuan, Jiajia and Shen, Lin and Liu, Tian Shu and Xu, HuiTing and Yang, Jianwei and Wei, Jia and Jiang, Haiping and Deng, Yanhong and Pan, Hongming and Wang, Yusheng and Zhang, Xiaotian and Peng, Zhi and Qi, Changsong and Zhang, Lingli and Hsu, Peiwen and Song, Lin and Mu, Lei and Sun, Qiao and Gong, Jifang and Lyu, Cheng},
  title = {Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.70091}
}
Kostenlos starten →